{"denoms":[{"counts":[{"groupId":"BG000","value":"81"}],"units":"Participants"}],"groups":[{"description":"Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.\n\nPegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide.\n\nRituximab: 375 mg/m\\^2/day on Days 1, 4, 8, 11, 45, and 52.\n\nCyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.","id":"BG000","title":"R-HiCy"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"71"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"81"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"81"}],"units":"Participants"}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"BG000","value":"59"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"81"}],"units":"Participants"}],"title":"Male"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"81"}],"units":"Participants"}],"title":"Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"}]}